Cited by 587DNA Repair MechanismsCancer-related Molecular PathwaysCancer Genomics and Diagnostics

The DOI matches its Crossref record; 113 of the 113 references it cites were found in a registry or an index.

Therapeutic opportunities within the DNA damage response

Open access

Pearl, Laurence H., Schierz, Amanda C., Ward, Simon E., Al-Lazikani, Bissan, Pearl, Frances M. G.·2015·Nature Reviews Cancer

DOI 10.1038/nrc3891

Open this paper in CoChat — free account

Abstract

The DNA damage response (DDR) is essential for maintaining the genomic integrity of the cell, and its disruption is one of the hallmarks of cancer. Classically, defects in the DDR have been exploited therapeutically in the treatment of cancer with radiation therapies or genotoxic chemotherapies. More recently, protein components of the DDR systems have been identified as promising avenues for targeted cancer therapeutics. Here, we present an in-depth analysis of the function, role in cancer and therapeutic potential of 450 expert-curated human DDR genes. We discuss the DDR drugs that have been approved by the US Food and Drug Administration (FDA) or that are under clinical investigation. We examine large-scale genomic and expression data for 15 cancers to identify deregulated components of the DDR, and we apply systematic computational analysis to identify DDR proteins that are amenable to modulation by small molecules, highlighting potential novel therapeutic targets.

Integrity signals

Registry

Crossref · 10.1038/nrc3891

Cites

113 of 113 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Gene Ontology: tool for the unification of biology
Ashburner, M., Ball, C. A., Blake, J. A., Botstein, D., Butler, H., Cherry, J. M., Davis, A. P., Dolinski, K., Dwight, S. S., Eppig, J. T., et al. (2000) · Nature Genetics · doi:10.1038/75556 · Cited by 43,206
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989
Evaluation of Factors Related to Late Recurrence - Later than 10 Years after the Initial Treatment - in Primary Breast Cancer
Nishimura, R., Osako, T., Nishiyama, Y., Tashima, R., Nakano, M., Fujisue, M., Toyozumi, Y., & Arima, N. (2013) · Oncology · doi:10.1159/000353099 · Cited by 13,239
Comprehensive molecular portraits of human breast tumours
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11412 · Cited by 12,129
Gephi: An Open Source Software for Exploring and Manipulating Networks
Bastian, M., Heymann, S., & Jacomy, M. (2009) · Proceedings of the International AAAI Conference on Web and Social Media · doi:10.1609/icwsm.v3i1.13937 · Cited by 11,675
Signatures of mutational processes in human cancer
Initiative, A. P. C. G., Alexandrov, L. B., ICGC Breast Cancer Consortium, ICGC MMML-Seq Consortium, PedBrain, I., Nik-Zainal, S., Wedge, D. C., Aparicio, S. A. J. R., Behjati, S., Biankin, A. V., et al. (2013) · Nature · doi:10.1038/nature12477 · Cited by 9,660
The cancer genome atlas pan-cancer analysis project
The Cancer Genome Atlas Research Network, Weinstein, J. N., Collisson, E. A., Mills, G. B., Shaw, K. R. M., Ozenberger, B. A., Ellrott, K., Shmulevich, I., Sander, C., & Stuart, J. M. (2013) · Nature Genetics · doi:10.1038/ng.2764 · Cited by 9,092
Comprehensive molecular characterization of human colon and rectal cancer
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11252 · Cited by 8,499
Integrated genomic analyses of ovarian carcinoma
Perou, C. M. (2019) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/hvp3-wg08 · Cited by 7,927
Cancer Genome Landscapes
Vogelstein, B., Papadopoulos, N., Velculescu, V. E., Zhou, S., Diaz, L. A., & Kinzler, K. W. (2013) · Science · doi:10.1126/science.1235122 · Cited by 7,863

Flagged first, then by citations

Show all 112 references

Research works printed but not linked: 2

McKusick, V. A. A. Catalog of Human Genes and Genetic Disorders (John Hopkins Univ. Press, 1998).
Hoe, K. K., Verma, C. S. & Lane, D. P. Drugging the p53 pathway: understanding the route to clinical efficacy. Nature Rev. Drug Discov. 13, 217–236 (2014). · DOI

Sorted by citations

Pan-cancer analysis of whole genomes
The ICGC/TCGA Pan-Cancer Analysis of Whole Genomes Consortium, Aaltonen, L. A., Abascal, F., Abeshouse, A., Aburatani, H., Adams, D. J., Agrawal, N., Ahn, K. S., Ahn, S.-M., Aikata, H., et al. (2020) · Nature · doi:10.1038/s41586-020-1969-6 · Cited by 3,064
Targeting the DNA Damage Response in Cancer
O’Connor, M. J. (2015) · Molecular Cell · doi:10.1016/j.molcel.2015.10.040 · Cited by 1,602
Cell cycle control in cancer
Matthews, H. K., Bertoli, C., & de Bruin, R. A. M. (2022) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-021-00404-3 · Cited by 1,506
Genomic and Molecular Landscape of DNA Damage Repair Deficiency across The Cancer Genome Atlas
Knijnenburg, T., Wang, L., Zimmermann, M. T., Chambwe, N., Gao, G. F., Cherniack, A. D., Fan, H., Shen, H., Way, G. P., Greene, C. S., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.03.076 · Cited by 1,145
DNA damage repair: historical perspectives, mechanistic pathways and clinical translation for targeted cancer therapy
Huang, R., & Zhou, P. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00648-7 · Cited by 1,015
Revisiting the hallmarks of cancer.
Fouad, Y. A., & Aanei, C. M. (2017) · Europe PMC (PubMed Central) · Cited by 875
DNA repair, genome stability and cancer: a historical perspective
Jeggo, P. A., Pearl, L. H., & Carr, A. M. (2015) · Nature reviews. Cancer · doi:10.1038/nrc.2015.4 · Cited by 781
Self-citation
CAG Repeat Not Polyglutamine Length Determines Timing of Huntington’s Disease Onset
Lee, J., Correia, K., Loupe, J. M., Kim, K., Barker, D., Hong, E. P., Chao, M. J., Long, J. D., Lucente, D. E., Vonsattel, J. P., et al. (2019) · Cell · doi:10.1016/j.cell.2019.06.036 · Cited by 543
Overcoming cancer therapeutic bottleneck by drug repurposing
Zhang, Z., Zhou, L., Xie, N., Nice, E. C., Zhang, T., Cui, Y., & Huang, C. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00213-8 · Cited by 544
Melatonin, a Full Service Anti-Cancer Agent: Inhibition of Initiation, Progression and Metastasis
Reiter, R. J., Rosales‐Corral, S., Tan, D., Acuña-Castroviejo, D., Qin, L., Yang, S., & Xu, K. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18040843 · Cited by 453
Genetic Insights Into Biological Mechanisms Governing Human Ovarian Ageing
Ruth, K. S., Day, F. R., Hussain, J., Martínez-Marchal, A., Aiken, C., Azad, A., Thompson, D. J., Knoblochová, L., Abe, H., Tarry‐Adkins, J. L., et al. (2021) · Obstetrical & Gynecological Survey · doi:10.1038/s41586-021-03779-7 · Cited by 442
Mutational signatures in esophageal adenocarcinoma define etiologically distinct subgroups with therapeutic relevance
Secrier, M., Li, X., de Silva, N., Eldridge, M., Contino, G., Bornschein, J., MacRae, S., Grehan, N., O’Donovan, M., Miremadi, A., et al. (2016) · Nature Genetics · doi:10.1038/ng.3659 · Cited by 402
DNA Repair Pathways in Cancer Therapy and Resistance
Li, L.-Y., Guan, Y.-D., Chen, X.-S., Yang, J.-M., & Cheng, Y. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.629266 · Cited by 383
“Numerous studies have indicated that certain cancers are associated with the defect or mutation in the proteins of nuclear or mitochondrial DNA repair pathways (Pearl et al., 2015; Cerrato et al., 2016).”
Background
Lifestyle and dietary environmental factors in colorectal cancer susceptibility
Murphy, N., Moreno, V. R., Hughes, D. J., Vodicka, L., Vodička, P., Aglago, E. K., Gunter, M. J., & Jenab, M. (2019) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2019.06.005 · Cited by 335
Tumour treating fields therapy for glioblastoma: current advances and future directions
Rominiyi, O., Vanderlinden, A., Clenton, S. J., Bridgewater, C. H., Al-Tamimi, Y., & Collis, S. J. (2020) · British Journal of Cancer · doi:10.1038/s41416-020-01136-5 · Cited by 342
Report of the AAPM TG ‐256 on the relative biological effectiveness of proton beams in radiation therapy
Paganetti, H., Blakely, E. A., Cárabe, A., Carlson, D. J., Das, I. J., Dong, L., Grosshans, D. R., Held, K. D., Mohan, R., Moiseenko, V., et al. (2019) · Medical Physics · doi:10.1002/mp.13390 · Cited by 334
Identification of genetic variants associated with Huntington's disease progression: a genome-wide association study
Moss, D. J. H., Pardiñas, A. F., Langbehn, D., Lo, K., Leavitt, B. R., Roos, R., Durr, A., Mead, S., Coleman, A., Santos, R. D., et al. (2017) · The Lancet Neurology · doi:10.1016/s1474-4422(17)30161-8 · Cited by 312
Targeted Therapies for Triple-Negative Breast Cancer: Combating a Stubborn Disease
Kalimutho, M., Parsons, K., Mittal, D., López, J. A., Srihari, S., & Khanna, K. K. (2015) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2015.08.009 · Cited by 298
Genetic etiology of oral cancer
Ali, J., Sabiha, B., Jan, H., Haider, S. A., Khan, A. A., & Ali, S. (2017) · Oral Oncology · doi:10.1016/j.oraloncology.2017.05.004 · Cited by 279
Homologous recombination deficiency and ovarian cancer
Ledermann, J. A., Drew, Y., & Kristeleit, R. S. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2016.03.005 · Cited by 258
MRE11-RAD50-NBS1 complex alterations and DNA damage response: implications for cancer treatment
Bian, L., Meng, Y., Zhang, M., & Li, D. (2019) · Molecular Cancer · doi:10.1186/s12943-019-1100-5 · Cited by 267
Distinct Classes of Complex Structural Variation Uncovered across Thousands of Cancer Genome Graphs
Hadi, K., Yao, X., Behr, J. M., Deshpande, A. S., Xanthopoulakis, C., Tian, H., Kudman, S., Rosiene, J. A., Darmofal, M., DeRose, J., et al. (2020) · Cell · doi:10.1016/j.cell.2020.08.006 · Cited by 249
An Update on Poly(ADP-ribose)polymerase-1 (PARP-1) Inhibitors: Opportunities and Challenges in Cancer Therapy
Wang, Y.-Q., Wang, P., Wang, Y.-T., Yang, G., Zhang, A., & Miao, Z. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00055 · Cited by 251
ATM in DNA repair in cancer
Jin, M. H., & Oh, D. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.07.002 · Cited by 260
Mutational signatures are jointly shaped by DNA damage and repair
Volkova, N. V., Meier, B., González‐Huici, V., Bertolini, S., González, S., Vöhringer, H. S., Abascal, F., Martincorena, I., Campbell, P. J., Gartner, A., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-15912-7 · Cited by 227
Human female meiosis revised: new insights into the mechanisms of chromosome segregation and aneuploidies from advanced genomics and time-lapse imaging
Capalbo, A., Hoffmann, E. R., Cimadomo, D., Ubaldi, F. M., & Rienzi, L. F. (2017) · Human Reproduction Update · doi:10.1093/humupd/dmx026 · Cited by 221
STING enhances cell death through regulation of reactive oxygen species and DNA damage
Hayman, T. J., Baro, M., MacNeil, T., Phoomak, C., Aung, T. N., Cui, W., Leach, K., Iyer, R. P., Challa, S., Sandoval-Schaefer, T., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-22572-8 · Cited by 219
Moving From Poly (ADP-Ribose) Polymerase Inhibition to Targeting DNA Repair and DNA Damage Response in Cancer Therapy
Gourley, C., Balmañà, J., Ledermann, J. A., Serra, V., Dent, R. A., Loibl, S., Pujade-Lauraine, É., & Boulton, S. J. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.02050 · Cited by 195
Regulated cell death and adaptive stress responses
Galluzzi, L., Bravo-San Pedro, J. M., Kepp, O., & Kroemer, G. (2016) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-016-2209-y · Cited by 177
DNA Damage Response in Cancer Therapy and Resistance: Challenges and Opportunities
Jurkovičová, D., Neophytou, C. M., Gašparović, A. Č., & Gonçalves, A. C. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232314672 · Cited by 175
Inhibition of Topoisomerase (DNA) I (TOP1): DNA Damage Repair and Anticancer Therapy
Xu, Y., & Her, C. (2015) · Biomolecules · doi:10.3390/biom5031652 · Cited by 169
Melatonin: A pleiotropic molecule that modulates DNA damage response and repair pathways
Majidinia, M., Sadeghpour, A., Mehrzadi, S., Reiter, R. J., Khatami, N., & Yousefi, B. (2017) · Journal of Pineal Research · doi:10.1111/jpi.12416 · Cited by 171
DeepSMILE: Contrastive self-supervised pre-training benefits MSI and HRD classification directly from H&E whole-slide images in colorectal and breast cancer
Schirris, Y., Gavves, E., Nederlof, I., Horlings, H. M., & Teuwen, J. (2022) · Medical Image Analysis · doi:10.1016/j.media.2022.102464 · Cited by 174
Evaluating the molecule-based prediction of clinical drug responses in cancer
Ding, Z., Zu, S., & Gu, J. (2016) · Bioinformatics · doi:10.1093/bioinformatics/btw344 · Cited by 162
The RNA Splicing Response to DNA Damage
Shkreta, L., & Chabot, B. (2015) · Biomolecules · doi:10.3390/biom5042935 · Cited by 156
A new wave of innovations within the DNA damage response
Li, Q., Qian, W., Zhang, Y., Hu, L., Chen, S., & Xia, Y. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01548-8 · Cited by 166
Targeting Oxidatively Induced DNA Damage Response in Cancer: Opportunities for Novel Cancer Therapies
Davalli, P., Marverti, G., Lauriola, A., & D’Arca, D. (2018) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2018/2389523 · Cited by 156
Advances in Deubiquitinating Enzyme Inhibition and Applications in Cancer Therapeutics
Antao, A. M., Tyagi, A., Kim, K.-S., & Ramakrishna, S. (2020) · Cancers · doi:10.3390/cancers12061579 · Cited by 156
DNA damage response and resistance of cancer stem cells
Abad, E., Graifer, D., & Lyakhovich, A. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.01.008 · Cited by 148
Targeted Therapies for Ovarian Cancer
Grunewald, T., & Ledermann, J. A. (2016) · Best Practice & Research Clinical Obstetrics & Gynaecology · doi:10.1016/j.bpobgyn.2016.12.001 · Cited by 150
The molecular landscape of ETMR at diagnosis and relapse
Lambo, S., Gröbner, S. N., Rausch, T., Waszak, S. M., Schmidt, C., Gorthi, A., Romero, J. C., Mauermann, M., Brabetz, S., Krausert, S., et al. (2019) · Nature · doi:10.1038/s41586-019-1815-x · Cited by 151
A Platinum(IV) Anticancer Prodrug Targeting Nucleotide Excision Repair To Overcome Cisplatin Resistance
Wang, Z., Xu, Z., & Zhu, G. (2016) · Angewandte Chemie International Edition · doi:10.1002/anie.201608936 · Cited by 141
Targeting DNA damage repair in small cell lung cancer and the biomarker landscape
Sen, T., Gay, C. M., & Byers, L. A. (2018) · Translational Lung Cancer Research · doi:10.21037/tlcr.2018.02.03 · Cited by 138
canSAR: an updated cancer research and drug discovery knowledgebase
Tym, J. E., Mitsopoulos, C., Coker, E. A., Razaz, P., Schierz, A. C., Antolín, A. A., & Al‐Lazikani, B. (2015) · Nucleic Acids Research · doi:10.1093/nar/gkv1030 · Cited by 136
Self-citation
Bioinformatics in translational drug discovery
Wooller, S. K., Benstead-Hume, G., Chen, X., Ali, Y., & Pearl, F. M. G. (2017) · Bioscience Reports · doi:10.1042/bsr20160180 · Cited by 136
Self-citation
Variant classification in precision oncology
Leichsenring, J., Horak, P., Kreutzfeldt, S., Heining, C., Christopoulos, P., Volckmar, A., Neumann, O., Kirchner, M., Ploeger, C., Budczies, J., et al. (2019) · International Journal of Cancer · doi:10.1002/ijc.32358 · Cited by 131
Role of Rad51 and DNA repair in cancer: A molecular perspective
Laurini, E., Marson, D., Fermeglia, A., Aulić, S., Fermeglia, M., & Pricl, S. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107492 · Cited by 135
Use of poly ADP-ribose polymerase [PARP] inhibitors in cancer cells bearing DDR defects: the rationale for their inclusion in the clinic
Cerrato, A., Morra, F., & Celetti, A. (2016) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-016-0456-2 · Cited by 132
CHD1 loss sensitizes prostate cancer to DNA damaging therapy by promoting error-prone double-strand break repair
Shenoy, T., Boysen, G., Wang, M. Y., Xu, Q. Z., Guo, W., Koh, F. M., Wang, C., Zhang, L. Z., Wang, Y., Gil, V., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx165 · Cited by 128
canSAR: update to the cancer translational research and drug discovery knowledgebase
Coker, E. A., Mitsopoulos, C., Tym, J. E., Komianou, A., Kannas, C. C., Micco, P. D., Villasclaras-Fernández, E. D., Özer, B., Antolín, A. A., Workman, P., et al. (2018) · Nucleic Acids Research · doi:10.1093/nar/gky1129 · Cited by 121
Self-citation
The crosstalk between Wnt/β-catenin signaling pathway with DNA damage response and oxidative stress: Implications in cancer therapy
Karimian, A., Majidinia, M., Baghi, H. B., & Yousefi, B. (2017) · DNA repair · doi:10.1016/j.dnarep.2017.01.003 · Cited by 125
Whole-genome sequencing reveals genomic signatures associated with the inflammatory microenvironments in Chinese NSCLC patients
Wang, C., Yin, R. H., Dai, J., Gu, Y., Cui, S., Ma, H., Zhang, Z., Huang, J., Qin, N., Jiang, T., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-04492-2 · Cited by 115
Targeting DNA repair, DNA metabolism and replication stress as anti‐cancer strategies
Puigvert, J. C., Sanjiv, K., & Helleday, T. (2015) · FEBS Journal · doi:10.1111/febs.13574 · Cited by 117
Ubiquitin-specific protease 7 sustains DNA damage response and promotes cervical carcinogenesis
Su, D., Ma, S., Shan, L., Wang, Y., Wang, Y., Cao, C., Liu, B., Yang, C., Wang, L., Tian, S., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci120518 · Cited by 118
The rise and fall of poly(ADP-ribose): An enzymatic perspective
Pascal, J. M., & Ellenberger, T. (2015) · DNA repair · doi:10.1016/j.dnarep.2015.04.008 · Cited by 107
Repair of 8-oxoG:A mismatches by the MUTYH glycosylase: Mechanism, metals and medicine
Banda, D. M., Nuñez, N. N., Burnside, M. A., Bradshaw, K. M., & David, S. S. (2017) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2017.01.008 · Cited by 105
Stress management by autophagy: Implications for chemoresistance
Huang, Z., Zhou, L., Chen, Z., Nice, E. C., & Huang, C. (2016) · International Journal of Cancer · doi:10.1002/ijc.29990 · Cited by 105
Recent advances in platinum-based chemotherapeutics that exhibit inhibitory and targeted mechanisms of action
Khoury, A., Deo, K. M., & Aldrich-Wright, J. R. (2020) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2020.111070 · Cited by 100
DNA repair in the trinucleotide repeat disorders
Jones, L., Houlden, H., & Tabrizi, S. J. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(16)30350-7 · Cited by 101
Tyrosyl–DNA phosphodiesterases: rescuing the genome from the risks of relaxation
Kawale, A. S., & Povirk, L. F. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkx1219 · Cited by 101
CHK1-targeted therapy to deplete DNA replication-stressed, p53-deficient, hyperdiploid colorectal cancer stem cells
Manic, G., Signore, M., Sistigu, A., Russo, G., Corradi, F., Siteni, S., Musella, M., Vitale, S., De Angelis, M. L., Pallocca, M., et al. (2018) · Gut · doi:10.1136/gutjnl-2016-312623 · Cited by 98
Cellular senescence in gastrointestinal diseases: from pathogenesis to therapeutics
Frey, N., Venturelli, S., Zender, L., & Bitzer, M. (2018) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2017.146 · Cited by 97
SIRT6 coordinates with CHD4 to promote chromatin relaxation and DNA repair
Hou, T., Cao, Z., Zhang, J., Tang, M., Tian, Y., Li, Y., Lu, X., Chen, Y., Wang, H., Wei, F., et al. (2020) · Nucleic Acids Research · doi:10.1093/nar/gkaa006 · Cited by 96
The central role of DNA damage and repair in CAG repeat diseases
Massey, T. H., & Jones, L. (2018) · Disease Models & Mechanisms · doi:10.1242/dmm.031930 · Cited by 101
Genomic signatures reveal DNA damage response deficiency in colorectal cancer brain metastases
Sun, J., Wang, C., Zhang, Y., Xu, L., Fang, W. J., Zhu, Y., Zheng, Y., Chen, X., Xie, X., Hu, X., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-10987-3 · Cited by 95
canSAR: update to the cancer translational research and drug discovery knowledgebase
Mitsopoulos, C., Micco, P. D., Villasclaras-Fernández, E. D., Dolciami, D., Holt, E., Mica, I. L., Coker, E. A., Tym, J. E., Campbell, J., Che, K. H., et al. (2020) · Nucleic Acids Research · doi:10.1093/nar/gkaa1059 · Cited by 94
Self-citation
Deficiency of nucleotide excision repair is associated with mutational signature observed in cancer
Jager, M., Blokzijl, F., Kuijk, E., Bertl, J., Vougioukalaki, M., Janssen, R., Besselink, N., Boymans, S., de Ligt, J., Pedersen, J. S., et al. (2019) · Genome Research · doi:10.1101/gr.246223.118 · Cited by 98
Whole-genome sequencing reveals clinically relevant insights into the aetiology of familial breast cancers
Nones, K., Johnson, J., Newell, F., Patch, A. M., Thorne, H., Kazakoff, S. H., de Luca, X. M., Parsons, M. T., Ferguson, K., Reid, L. E., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz132 · Cited by 93
“No evidence of biallelic inactivation in 52 HR-related genes [12] were identified in this case (supplementary Tables S3–S6, available at Annals of Oncology online).”
Background
Proteins from the DNA Damage Response: Regulation, Dysfunction, and Anticancer Strategies
Molinaro, C., Martoriati, A., & Cailliau, K. (2021) · Cancers · doi:10.3390/cancers13153819 · Cited by 99
Genotoxic stress triggers the activation of IRE1α-dependent RNA decay to modulate the DNA damage response
Dufey, E., Pedro, J. M. B., Eggers, C., González-Quiroz, M., Urra, H., Sagredo, A. I., Sepúlveda, D., Pihán, P., Carreras‐Sureda, A., Hazari, Y., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-15694-y · Cited by 92
DNA repair and damage pathways in breast cancer development and therapy
Majidinia, M., & Yousefi, B. (2017) · DNA repair · doi:10.1016/j.dnarep.2017.03.009 · Cited by 92
The Future of Radiobiology
Kirsch, D. G., Diehn, M., Kesarwala, A. H., Maity, A. M., Morgan, M. A., Schwarz, J. K., Bristow, R. G., Demaria, S., Eke, I., Griffin, R. J., et al. (2017) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djx231 · Cited by 96
DNA damage responses in cancer stem cells: Implications for cancer therapeutic strategies
Wang, Q. (2015) · World Journal of Biological Chemistry · doi:10.4331/wjbc.v6.i3.57 · Cited by 92
Cytoplasmic RAP1 mediates cisplatin resistance of non-small cell lung cancer
Xiao, L., Lan, X., Shi, X., Zhao, K., Wang, D., Wang, X., Li, F., Huang, H., & Liu, J. (2017) · Cell Death and Disease · doi:10.1038/cddis.2017.210 · Cited by 90
Cell cycle dysregulation in cancer
Glaviano, A., Singh, S. K., Lee, E. H. C., Okina, E., Lam, H. Y., Carbone, D., Reddy, E. P., O’Connor, M. J., Koff, A., Singh, G., et al. (2024) · Pharmacological Reviews · doi:10.1016/j.pharmr.2024.100030 · Cited by 98
Overexpression of Flap Endonuclease 1 Correlates with Enhanced Proliferation and Poor Prognosis of Non–Small-Cell Lung Cancer
Zhang, K., Keymeulen, S., Nelson, R. A., Tong, T. R. S.-W., Yuan, Y., Yun, X., Liu, Z., Lopez, J., Raz, D. J., & Kim, J. Y. (2017) · American Journal Of Pathology · doi:10.1016/j.ajpath.2017.09.011 · Cited by 87
Polyphenols: Major regulators of key components of DNA damage response in cancer
Majidinia, M., Bishayee, A., & Yousefi, B. (2019) · DNA repair · doi:10.1016/j.dnarep.2019.102679 · Cited by 87
The DNA methylome of DDR genes and benefit from RT or TMZ in IDH mutant low-grade glioma treated in EORTC 22033
Bady, P., Kurscheid, S., Delorenzi, M., Gorlia, T., van den Bent, M. J., Hoang‐Xuan, K., Vauléon, É., Gijtenbeek, A., Enting, R. H., Thiessen, B. A., et al. (2018) · Acta Neuropathologica · doi:10.1007/s00401-018-1810-6 · Cited by 87
DNA Damage Response and Repair Pathway Alteration and Its Association With Tumor Mutation Burden and Platinum-Based Chemotherapy in SCLC
Park, S., Lee, H., Lee, B., Lee, S., Sun, J., Park, W., Ahn, J. S., Ahn, M., & Park, K. (2019) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2019.05.014 · Cited by 87
Synthetic Lethality and Cancer – Penetrance as the Major Barrier
Ryan, C. J., Bajrami, I., & Lord, C. J. (2018) · Trends in cancer · doi:10.1016/j.trecan.2018.08.003 · Cited by 91
Multifunctional Magnetoliposomes for Sequential Controlled Release
Salvatore, A., Montis, C., Berti, D., & Baglioni, P. (2016) · ACS Nano · doi:10.1021/acsnano.6b03194 · Cited by 85
Nanoparticles for siRNA-Based Gene Silencing in Tumor Therapy
Babu, A., Muralidharan, R., Amreddy, N., Mehta, M., Munshi, A., & Ramesh, R. (2016) · IEEE Transactions on NanoBioscience · doi:10.1109/tnb.2016.2621730 · Cited by 84
DNA damage response regulation by microRNAs as a therapeutic target in cancer
Majidinia, M., & Yousefi, B. (2016) · DNA repair · doi:10.1016/j.dnarep.2016.09.003 · Cited by 84
MiRNA-Based Therapies for Lung Cancer: Opportunities and Challenges?
Yang, H. K., Liu, Y., Chen, L., Zhao, J., Guo, M., Zhao, X., Wen, Z., He, Z., Chen, C., & Xu, L. (2023) · Biomolecules · doi:10.3390/biom13060877 · Cited by 81
Integrated multi-omics approach to distinct molecular characterization and classification of early-onset colorectal cancer
Du, M., Gu, D., Xin, J., Peters, U., Song, M., Cai, G., Li, S., Ben, S., Meng, Y., Chu, H., et al. (2023) · Cell Reports Medicine · doi:10.1016/j.xcrm.2023.100974 · Cited by 81
Targeting HDAC3, a new partner protein of AKT in the reversal of chemoresistance in acute myeloid leukemia via DNA damage response
Long, J., Fang, W. Y., Chang, L., Gao, W. H., Shen, Y., Jia, M. Y., Zhang, Y. X., Wang, Y., Dou, H. B., Zhang, W. J., et al. (2017) · Leukemia · doi:10.1038/leu.2017.130 · Cited by 78
Genomic hallmarks and therapeutic implications of G0 cell cycle arrest in cancer
Wiecek, A. J., Cutty, S. J., Kornai, D., Parreno-Centeno, M., Gourmet, L. E., Tagliazucchi, G. M., Jacobson, D. H., Zhang, P., Xiong, L., Bond, G. L., et al. (2023) · Genome biology · doi:10.1186/s13059-023-02963-4 · Cited by 83
Synthetic lethal strategies for the development of cancer therapeutics
Ngoi, N. Y. L., Gallo, D., Torrado, C., Nardo, M., Durocher, D., & Yap, T. A. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-024-00966-z · Cited by 81
DNA damage response and repair in colorectal cancer: Defects, regulation and therapeutic implications
Mirza‐Aghazadeh‐Attari, M., Darband, S. G., Kaviani, M., Mihanfar, A., Aghazadeh-Attari, J., Yousefi, B., & Majidinia, M. (2018) · DNA repair · doi:10.1016/j.dnarep.2018.07.005 · Cited by 79
Drug resistance‐related microRNAs in osteosarcoma: Translating basic evidence into therapeutic strategies
Chen, R., Wang, G., Zheng, Y., Hua, Y., & Cai, Z. (2019) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.14064 · Cited by 77
The Effects of Localized Heat on the Hallmarks of Cancer
Hannon, G., Tansi, F. L., Hilger, I., & Prina‐Mello, A. (2021) · Advanced Therapeutics · doi:10.1002/adtp.202000267 · Cited by 77
Non-Coding RNAs and Resistance to Anticancer Drugs in Gastrointestinal Tumors
Hahne, J. C., & Valeri, N. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00226 · Cited by 74
Potent therapeutic strategy in gastric cancer with microsatellite instability-high and/or deficient mismatch repair
Ooki, A., Osumi, H., Yoshino, K., & Yamaguchi, K. (2024) · Gastric Cancer · doi:10.1007/s10120-024-01523-4 · Cited by 76
The Synergistic Effect of PARP Inhibitors and Immune Checkpoint Inhibitors
Wu, Z., Cui, P., Tao, H., Zhang, S., Ma, J., Liu, Z., Wang, J., Qian, Y., Chen, S., Huang, Z., et al. (2021) · Clinical Medicine Insights Oncology · doi:10.1177/1179554921996288 · Cited by 72
The spectrum of APOBEC3 activity: From anti-viral agents to anti-cancer opportunities
Green, A. M., & Weitzman, M. D. (2019) · DNA repair · doi:10.1016/j.dnarep.2019.102700 · Cited by 75
Genomic analysis of DNA repair genes and androgen signaling in prostate cancer
Jividen, K., Kedzierska, K., Yang, C., Szlachta, K. A., Ratan, A., & Paschal, B. M. (2018) · BMC Cancer · doi:10.1186/s12885-018-4848-x · Cited by 68
Genetic modifiers of Mendelian disease: Huntington’s disease and the trinucleotide repeat disorders
Holmans, P., Massey, T. H., & Jones, L. (2017) · Human Molecular Genetics · doi:10.1093/hmg/ddx261 · Cited by 69
Cdk5 links with DNA damage response and cancer
Liu, W., Li, J., Song, Y., Li, Y., Jia, Y., & Zhao, H. (2017) · Molecular Cancer · doi:10.1186/s12943-017-0611-1 · Cited by 67
Selinexor reduces the expression of DNA damage repair proteins and sensitizes cancer cells to DNA damaging agents
Kashyap, T., Argueta, C. E., Unger, T. J., Klebanov, B., Debler, S., Senapedis, W. T., Crochiere, M. L., Lee, M. S., Kauffman, M. G., Shacham, S., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.25637 · Cited by 64
CHK1 inhibitor sensitizes resistant colorectal cancer stem cells to nortopsentin
Franco, S. D., Parrino, B., Gaggianesi, M., Pantina, V. D., Bianca, P., Nicotra, A., Mangiapane, L. R., Iacono, M. L., Ganduscio, G., Veschi, V., et al. (2021) · iScience · doi:10.1016/j.isci.2021.102664 · Cited by 65

Authors: Pearl, L. H., Schierz, A. C., Ward, S. E., Al-Lazikani, B., & Pearl, F. M. G.
Affiliations: University of Sussex (GB)
Institute of Cancer Research (GB)
Corresponding author: Pearl, Frances M. G.
ORCID: Pearl, Laurence H.
Ward, Simon E.
Pearl, Frances M. G.
Venue: Nature Reviews Cancer
Publisher: Springer Science and Business Media LLC
Published: 2015-02-24
Volume: 15
Issue: 3
Pages: 166-180
ISSN: 1474-175X (ISSN-L)
1474-1768
DOI: 10.1038/nrc3891
OpenAlex: W2065087624
Cited by: 587
References: 112
Citations by year: 2026: 22 · 2025: 42 · 2024: 66 · 2023: 56 · 2022: 57 · 2021: 66 · 2020: 59 · 2019: 49 · 2018: 49 · 2017: 60 · 2016: 45 · 2015: 16
FWCI: 5.49
Type: journal article
Language: en
Open access: green
figshare.com
Licence: cc-by
www.springer.com/tdm (tdm)
Locations: Nature reviews. Cancer (publishedVersion)
PubMed (publishedVersion)
Sussex Research Online (University of Sussex) (submittedVersion)
Figshare (submittedVersion, cc-by)
ORCA Online Research @Cardiff (Cardiff University) (submittedVersion)
Funders: Cancer Research UK (C309/A11566, 11566, C302/A14532, 14532)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › DNA Repair Mechanisms
Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
Keywords: DNA damage response, synthetic lethality, targeted cancer therapy, therapeutic target, genome stability, cancer genomics
MeSH terms: DNA Damage, DNA Repair, Humans, Neoplasms

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Therapeutic opportunities within the DNA damage response

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks